Safety of IL-23 p19 Inhibitors for the Treatment of Patients With Moderate-to-Severe Plaque Psoriasis: A Narrative Review
In conclusion, the favorable safety profiles of IL-23 p19 inhibitors support their long-term use in the management of patients with moderate-to-severe psoriasis.
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More News: Arthritis | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Clinical Trials | Common Cold | Diabetes | Drugs & Pharmacology | Eating Disorders & Weight Management | Endocrinology | Headache | Heart | Hypertension | Inflammatory Bowel Disease | Metabolic Syndrome | Migraine | Nonmelanoma Skin Cancer | Obesity | Oral Cancer | Psoriasis | Psoriatic Arthritis | Respiratory Medicine | Rheumatology | Skin | Skin Cancer | Study | Tuberculosis